Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244244 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
A Phase 2 study, sponsored by CytRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00244244: Completed Phase 2 study, sponsored by CytRx.
NCT00244244 is a Phase 2 study that has completed, run by CytRx. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244244, a Phase 2 study, has completed, sponsored by CytRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.
Interventions
- DRUG arimoclomol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00244244 record still lists
NCT00244244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 1 intervention - of which arimoclomol is the first listed.
NCT00244244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00244244 about?
NCT00244244 is a clinical study titled "A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS". The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.
What is the current status of trial NCT00244244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-10. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00244244?
The interventions under investigation include: arimoclomol (DRUG).
Who is sponsoring clinical trial NCT00244244?
This trial is sponsored by CytRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00244244's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia